Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Elicio Therapeutics (ELTX) Other Non-Current Liabilities (2022 - 2026)

Elicio Therapeutics filings provide 2 years of Other Non-Current Liabilities readings, the most recent being $11000.0 for Q4 2023.

  • On a quarterly basis, Other Non-Current Liabilities changed N/A to $11000.0 in Q4 2023 year-over-year; TTM through Dec 2023 was $11000.0, a N/A change, with the full-year FY2023 number at $11000.0, changed N/A from a year prior.
  • Other Non-Current Liabilities hit $11000.0 in Q4 2023 for Elicio Therapeutics, down from $81000.0 in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $220000.0 in Q1 2022 to a low of $11000.0 in Q4 2023.